• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

miR-125b上调miR-34a并依次激活多发性骨髓瘤中的应激适应和细胞死亡机制。

miR-125b Upregulates miR-34a and Sequentially Activates Stress Adaption and Cell Death Mechanisms in Multiple Myeloma.

作者信息

Misso Gabriella, Zarone Mayra Rachele, Lombardi Angela, Grimaldi Anna, Cossu Alessia Maria, Ferri Carmela, Russo Margherita, Vuoso Daniela Cristina, Luce Amalia, Kawasaki Hiromichi, Di Martino Maria Teresa, Virgilio Antonella, Festa Agostino, Galeone Aldo, De Rosa Giuseppe, Irace Carlo, Donadelli Massimo, Necas Alois, Amler Evzen, Tagliaferri Pierosandro, Tassone Pierfrancesco, Caraglia Michele

机构信息

Department of Precision Medicine, University of Campania "Luigi Vanvitelli," 80138 Naples, Italy.

Department of Precision Medicine, University of Campania "Luigi Vanvitelli," 80138 Naples, Italy.

出版信息

Mol Ther Nucleic Acids. 2019 Jun 7;16:391-406. doi: 10.1016/j.omtn.2019.02.023. Epub 2019 Mar 13.

DOI:10.1016/j.omtn.2019.02.023
PMID:31009917
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6479071/
Abstract

miR-125b, ubiquitously expressed and frequently dysregulated in several tumors, has gained special interest in the field of cancer research, displaying either oncogenic or oncosuppressor potential based on tumor type. We have previously demonstrated its tumor-suppressive role in multiple myeloma (MM), but the analysis of molecular mechanisms needs additional investigation. The purpose of this study was to explore the effects of miR-125b and its chemically modified analogs in modulating cell viability and cancer-associated molecular pathways, also focusing on the functional aspects of stress adaptation (autophagy and senescence), as well as programmed cell death (apoptosis). Based on the well-known low microRNA (miRNA) stability in therapeutic application, we designed chemically modified miR-125b mimics, laying the bases for their subsequent investigation in in vivo models. Our study clearly confirmed an oncosuppressive function depending on the repression of multiple targets, and it allowed the identification, for the first time, of miR-125b-dependent miR-34a stimulation as a possible consequence of the inhibitory role on the interleukin-6 receptor (IL-6R)/signal transducer and activator of transcription 3 (STAT3)/miR-34a feedback loop. Moreover, we identified a pattern of miR-125b-co-regulated miRNAs, shedding light on possible new players of anti-MM activity. Finally, functional studies also revealed a sequential activation of senescence, autophagy, and apoptosis, thus indicating, for the first two processes, an early cytoprotective and inhibitory role from apoptosis activation.

摘要

miR-125b在多种肿瘤中普遍表达且经常失调,在癌症研究领域引起了特别关注,根据肿瘤类型显示出致癌或抑癌潜力。我们之前已经证明了它在多发性骨髓瘤(MM)中的肿瘤抑制作用,但分子机制的分析还需要进一步研究。本研究的目的是探索miR-125b及其化学修饰类似物在调节细胞活力和癌症相关分子途径方面的作用,同时关注应激适应(自噬和衰老)以及程序性细胞死亡(凋亡)的功能方面。基于治疗应用中众所周知的微小RNA(miRNA)稳定性较低的情况,我们设计了化学修饰的miR-125b模拟物,为其随后在体内模型中的研究奠定基础。我们的研究清楚地证实了一种依赖于多个靶点抑制的抑癌功能,并且首次确定了miR-125b依赖的miR-34a刺激可能是其对白细胞介素-6受体(IL-6R)/信号转导和转录激活因子3(STAT3)/miR-34a反馈环抑制作用的结果。此外,我们确定了miR-125b共同调节的miRNA模式,揭示了抗MM活性可能的新参与者。最后,功能研究还揭示了衰老、自噬和凋亡的顺序激活,因此表明前两个过程对凋亡激活具有早期细胞保护和抑制作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b98/6479071/10f61f251599/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b98/6479071/3cb4282bde03/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b98/6479071/40aaf4e1bf5b/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b98/6479071/830c8c721cbc/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b98/6479071/d59fed058340/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b98/6479071/10f61f251599/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b98/6479071/3cb4282bde03/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b98/6479071/40aaf4e1bf5b/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b98/6479071/830c8c721cbc/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b98/6479071/d59fed058340/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b98/6479071/10f61f251599/gr5.jpg

相似文献

1
miR-125b Upregulates miR-34a and Sequentially Activates Stress Adaption and Cell Death Mechanisms in Multiple Myeloma.miR-125b上调miR-34a并依次激活多发性骨髓瘤中的应激适应和细胞死亡机制。
Mol Ther Nucleic Acids. 2019 Jun 7;16:391-406. doi: 10.1016/j.omtn.2019.02.023. Epub 2019 Mar 13.
2
MiR-125b suppresses bladder Cancer cell growth and triggers apoptosis by regulating IL-6/IL-6R/STAT3 axis in vitro and in vivo.微小RNA-125b通过在体外和体内调节白细胞介素-6/白细胞介素-6受体/信号转导和转录激活因子3轴来抑制膀胱癌细胞生长并引发细胞凋亡。
Cytokine. 2025 Jun;190:156926. doi: 10.1016/j.cyto.2025.156926. Epub 2025 Mar 22.
3
Attenuation of dexamethasone-induced cell death in multiple myeloma is mediated by miR-125b expression.地塞米松诱导的骨髓瘤细胞死亡的衰减是由 miR-125b 的表达介导的。
Cell Cycle. 2013 Jul 1;12(13):2144-53. doi: 10.4161/cc.25251. Epub 2013 Jun 11.
4
Erratum: miR-125b Upregulates miR-34a and Sequentially Activates Stress Adaption and Cell Death Mechanisms in Multiple Myeloma.勘误:miR-125b上调miR-34a并依次激活多发性骨髓瘤中的应激适应和细胞死亡机制。
Mol Ther Nucleic Acids. 2024 Oct 15;35(4):102354. doi: 10.1016/j.omtn.2024.102354. eCollection 2024 Dec 10.
5
miR-34a-5p and miR-125b-5p attenuate Aβ-induced neurotoxicity through targeting BACE1.微小RNA-34a-5p和微小RNA-125b-5p通过靶向β-分泌酶1减轻β-淀粉样蛋白诱导的神经毒性。
J Neurol Sci. 2020 Jun 15;413:116793. doi: 10.1016/j.jns.2020.116793. Epub 2020 Mar 20.
6
Inhibiting Glucose Metabolism By miR-34a and miR-125b Protects Against Hyperglycemia-Induced Cardiomyocyte Cell Death.通过miR-34a和miR-125b抑制葡萄糖代谢可预防高血糖诱导的心肌细胞死亡。
Arq Bras Cardiol. 2021 Mar;116(3):415-422. doi: 10.36660/abc.20190529.
7
MicroRNA-125b promotes apoptosis by regulating the expression of Mcl-1, Bcl-w and IL-6R.MicroRNA-125b 通过调节 Mcl-1、Bcl-w 和 IL-6R 的表达促进细胞凋亡。
Oncogene. 2013 Jun 20;32(25):3071-9. doi: 10.1038/onc.2012.318. Epub 2012 Jul 23.
8
Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo.通过合成的微小RNA-125b-5p模拟物对IRF4进行选择性靶向在体外和体内诱导抗多发性骨髓瘤活性。
Leukemia. 2015 Nov;29(11):2173-83. doi: 10.1038/leu.2015.124. Epub 2015 May 19.
9
The miRNA, miR-125b, Inhibited Invasion and Metastasis of Gastric-Cancer Cells by Triggering the STAT3 Signaling Pathway.微小RNA miR-125b通过激活信号转导和转录激活因子3(STAT3)信号通路抑制胃癌细胞的侵袭和转移。
Cancer Manag Res. 2020 Sep 17;12:8569-8580. doi: 10.2147/CMAR.S259513. eCollection 2020.
10
IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis.IL-6R/STAT3/miR-34a 反馈环促进 EMT 介导的结直肠癌侵袭和转移。
J Clin Invest. 2014 Apr;124(4):1853-67. doi: 10.1172/JCI73531. Epub 2014 Mar 18.

引用本文的文献

1
miRNA-Mediated Mechanisms in the Generation of Effective and Safe Oncolytic Viruses.微小RNA介导的有效且安全的溶瘤病毒产生机制
Pharmaceutics. 2024 Jul 25;16(8):986. doi: 10.3390/pharmaceutics16080986.
2
Identification and bioinformatic characterization of a serum miRNA signature for early detection of laryngeal squamous cell carcinoma.鉴定和生物信息学分析用于早期检测喉鳞癌的血清 miRNA 特征。
J Transl Med. 2024 Jul 10;22(1):647. doi: 10.1186/s12967-024-05385-3.
3
Identification of Tissue miRNA Signatures for Pancreatic Ductal Adenocarcinoma.

本文引用的文献

1
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92.靶向 pri-miR-17-92 的首创抑制剂 MIR17PTi 对多发性骨髓瘤的治疗易感性
Blood. 2018 Sep 6;132(10):1050-1063. doi: 10.1182/blood-2018-03-836601. Epub 2018 Jul 11.
2
MicroRNA-542-3p suppresses tumor cell proliferation via targeting Smad2 inhuman osteosarcoma.微小RNA-542-3p通过靶向Smad2抑制人骨肉瘤肿瘤细胞增殖。
Oncol Lett. 2018 May;15(5):6895-6902. doi: 10.3892/ol.2018.8238. Epub 2018 Mar 12.
3
Let-7c inhibits cholangiocarcinoma growth but promotes tumor cell invasion and growth at extrahepatic sites.
胰腺导管腺癌组织微小RNA特征的鉴定
Cancers (Basel). 2024 Feb 18;16(4):824. doi: 10.3390/cancers16040824.
4
MicroRNA-125b as a valuable predictive marker for outcome after autologous hematopoietic stem cell transplantation.微小 RNA-125b 作为自体造血干细胞移植后预后的有价值的预测标志物。
BMC Cancer. 2023 Mar 3;23(1):202. doi: 10.1186/s12885-023-10665-0.
5
MiRNA as a Potential Target for Multiple Myeloma Therapy-Current Knowledge and Perspectives.微小RNA作为多发性骨髓瘤治疗的潜在靶点——当前认知与展望
J Pers Med. 2022 Aug 31;12(9):1428. doi: 10.3390/jpm12091428.
6
The Multiple Myeloma Landscape: Epigenetics and Non-Coding RNAs.多发性骨髓瘤全景:表观遗传学与非编码RNA
Cancers (Basel). 2022 May 10;14(10):2348. doi: 10.3390/cancers14102348.
7
The HGF/c-MET axis as a potential target to overcome survival signals and improve therapeutic efficacy in multiple myeloma.HGF/c-MET轴作为克服生存信号并提高多发性骨髓瘤治疗疗效的潜在靶点。
Cancer Drug Resist. 2021 Oct 21;4(4):923-933. doi: 10.20517/cdr.2021.73. eCollection 2021.
8
Overview on Molecular Biomarkers for Laryngeal Cancer: Looking for New Answers to an Old Problem.喉癌分子生物标志物概述:探寻一个老问题的新答案
Cancers (Basel). 2022 Mar 28;14(7):1716. doi: 10.3390/cancers14071716.
9
Evaluation of the expressed miR-129 and miR-549a in patients with multiple sclerosis.多发性硬化症患者中表达的miR-129和miR-549a的评估。
Adv Biomed Res. 2021 Dec 25;10:48. doi: 10.4103/abr.abr_268_20. eCollection 2021.
10
A Cancer-Related microRNA Signature Shows Biomarker Utility in Multiple Myeloma.一种与癌症相关的 microRNA 特征可作为多发性骨髓瘤的生物标志物。
Int J Mol Sci. 2021 Dec 5;22(23):13144. doi: 10.3390/ijms222313144.
Let-7c 抑制胆管癌生长,但促进肿瘤细胞在肝外部位的侵袭和生长。
Cell Death Dis. 2018 Feb 14;9(2):249. doi: 10.1038/s41419-018-0286-6.
4
MiR-539 inhibits proliferation and migration of triple-negative breast cancer cells by down-regulating LAMA4 expression.微小RNA-539通过下调层粘连蛋白α4表达抑制三阴性乳腺癌细胞的增殖和迁移。
Cancer Cell Int. 2018 Jan 30;18:16. doi: 10.1186/s12935-018-0512-4. eCollection 2018.
5
Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment.新型 miR-34a 为基础的治疗方法在多发性骨髓瘤治疗中的应用证据。
Sci Rep. 2017 Dec 20;7(1):17949. doi: 10.1038/s41598-017-18186-0.
6
Tumour-suppressive microRNA-424-5p directly targets CCNE1 as potential prognostic markers in epithelial ovarian cancer.抑瘤 microRNA-424-5p 可直接靶向 CCNE1,作为上皮性卵巢癌潜在的预后标志物。
Cell Cycle. 2018;17(3):309-318. doi: 10.1080/15384101.2017.1407894. Epub 2018 Jan 2.
7
The MiR-495/Annexin A3/P53 Axis Inhibits the Invasion and EMT of Colorectal Cancer Cells.微小RNA-495/膜联蛋白A3/P53轴抑制结肠癌细胞的侵袭和上皮-间质转化
Cell Physiol Biochem. 2017;44(5):1882-1895. doi: 10.1159/000485877. Epub 2017 Dec 8.
8
Upregulation of miR-542-3p inhibits the growth and invasion of human colon cancer cells through PI3K/AKT/survivin signaling.miR-542-3p 的上调通过 PI3K/AKT/survivin 信号通路抑制人结肠癌细胞的生长和侵袭。
Oncol Rep. 2017 Dec;38(6):3545-3553. doi: 10.3892/or.2017.6054. Epub 2017 Oct 23.
9
MicroRNA-125a-3p downregulation correlates with tumorigenesis and poor prognosis in patients with non-small cell lung cancer.MicroRNA-125a-3p表达下调与非小细胞肺癌患者的肿瘤发生及不良预后相关。
Oncol Lett. 2017 Oct;14(4):4441-4448. doi: 10.3892/ol.2017.6809. Epub 2017 Aug 24.
10
Non-coding RNAs as a new dawn in tumor diagnosis.非编码 RNA 作为肿瘤诊断的新曙光。
Semin Cell Dev Biol. 2018 Jun;78:37-50. doi: 10.1016/j.semcdb.2017.07.035. Epub 2017 Jul 29.